Dr Mario Cario previously served as International Director and Senior Partner at Sofimac Partners, currently Venture Partner at Sofimac Innovation Paris, Mario has raised and managed several Venture Capital Funds with 40+ Healthcare Companies and cumulated over 20 direct investments and management in Life Science companies , recording up to 26% IRR. Recently exited Centervue SpA for approx 70m€ .
Mario has gathered a broad experience spanning from researcher to entrepreneur and investor across a spectrum of markets. He expanded internationally the managed funds with focus on Healthcare cumulating100m+€ of direct funds raising in Seed and Development Funds.
Mario co-founded and managed his first Company, Spinelix, which was focused on devices for diagnostic and medical imaging, including an In Vitro Diagnostic subsidiary and closed several rounds of financing and major commercial contracts.
Researcher at CERN Geneva, he led major consortia in EU raising over 15mEURO. He filed and licensed several patents and wrote hundreds of scientific papers and a book in Statistics for Researchers in Life Science. He was Chair in Medical Biophysics and taught Health Technology Assesment.
Chairman of the Board
Dr Roberto Gradnik leverages his initial medical training as a cardiologist into his long term roles as a senior executive in the Biotech industry.
Roberto serves as CEO for a clinical stage biopharmaceutical company, focusing on urinary tract disorders.
He was formerly CEO of Stallergenes, based in Paris, and responsible for the M&A with Greer. Prior to Stallergenes, he served as EVP on the executive management board of MerckSerono, with responsibility for the Neurodegenerative, Autoimmune Diseases Therapeutic Area (TA) with total revenue in excess of over 1 billion$ and for Region Europe.
Roberto has also served as President of Assobiotech, Italy, and of EBE, Brussels.
Following his cardiology training, Roberto joined the pharmaceutical industry at Bracco, and gained experiences across several TAs, before joining Knoll (BASF Pharma) as Clinical Director responsible for development of treatment for cardiac ischemia.
Roberto serves on on several Boards, such as EBE (European Biopharmaceutical Entreprises), Zambon Pharmaceuticals
Chief Medical Officer (CMO)
Elisabeth received her MD and PhD from the University of Gothenburg and is a board-certified general surgeon and associate professor of surgery.
She joined Serono International based in Geneva Switzerland, initially in the field of metabolism, particularly wasting conditions, as a natural continuation of her academic and clinical work, before taking roles of increasing responsibilities at Serono/Merck Serono’s “New Therapies and Oncology Tas. Elisabeth subsequently joined Bristol Myers Squibb (BMS) in the United States in 2007. At BMS, Elisabeth served as development leader (2007 -2011) bringing dapagliflozin (Forxiga/Farxiga), a first in class medicine, to the market for the treatment of type 2 diabetes, and subsequently was Vice President and Head of the Intercontinental Medical Department responsible for Canada, Latin America, Middle East & Africa, Asia Pacific and Australia/New Zealand (2011- 2014).
In 2014 she joined Janssen Pharmaceuticals (a Johnson & Johnson Company) as Vice President, Head of the Established Products group managing a portfolio of 90 products, used by an estimated 150 million patients globally.
She currently serves as the Chief Development Officer for a clinical stage biopharmaceutical company, focusing on urinary tract disorders.
Elisabeth serves as a Non Executive Director on the following Boards: Galapagos (Belgium), Pharnext (France), PledPharma (Sweden), Swedish Orphan Biovitrum, SOBI (Sweden)
Nathalie de Valleuil
Nathalie holds a degree in Communication from – Ecole Supérieure de Publicité (ESP) in Paris and a certification in finance, cost control and reporting from HEC Paris.
She has a vast experience in administrative and financial management, and is responsible for all Kuste Biopharma financial, administration and communication duties.
Prior to joining Kuste Biopharma, Nathalie held a similar role for a clinical stage biopharmaceutical company, focusing on urinary tract disorders.
Nathalie has also served as Communication Director in International Advertising agencies in Paris and Geneva.